• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

VORINOSTAT Drug Record

  • Summary
  • Interactions
  • Claims
  • VORINOSTAT chembl:CHEMBL98 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    MK0683
    VORINOSTAT
    MK-0683
    ZOLINZA
    OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
    SHH
    SUBEROYLANILIDE HYDROXAMIC ACID
    SAHA
    SUBERANILOHYDROXAMIC ACID
    pubchem.compound:5311
    chembl:CHEMBL98
    chemidplus:149647-78-9
    drugbank:02546
    rxcui:194337

    Drug Info:

    Year of Approval 2006
    Drug Class antineoplastic agents
    FDA Approval Cutaneous T-cell lymphoma
    Drug Class Small molecule inhibitor
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (11 More Sources)

    Publications:

    Guerrant W et al., 2013, Dual-acting histone deacetylase-topoisomerase I inhibitors., Bioorg Med Chem Lett
    Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol
    Yang W et al., 2015, Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors., Bioorg Med Chem
    Daniel KB et al., 2015, Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release., J Med Chem
    Neelarapu R et al., 2011, Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes., J Med Chem
    Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
    Dallavalle S et al., 2009, Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors., Eur J Med Chem
    Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
    Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
    Pérez-Balado C et al., 2007, Bispyridinium dienes: histone deacetylase inhibitors with selective activities., J Med Chem
    Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
    Olson DE et al., 2013, Discovery of the first histone deacetylase 6/8 dual inhibitors., J Med Chem
    Xu et al., 2007, Histone deacetylase inhibitors: molecular mechanisms of action., Oncogene
    Day JA et al., 2013, Investigating the selectivity of metalloenzyme inhibitors., J Med Chem
    Dalgard et al., 2008, Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma., Clin. Cancer Res.
    Rushlow et al., 2013, Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies., Lancet Oncol.
    Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Mai A et al., 2008, Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities., Bioorg Med Chem Lett
    He et al., 2013, Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma., Cancer Discov
    Lee HY et al., 2014, Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells., J Med Chem
    Kemp MM et al., 2011, A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold., Bioorg Med Chem Lett
    Moffat D et al., 2010, Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor., J Med Chem
    Sodji QH et al., 2013, Synthesis and structure-activity relationship of 3-hydroxypyridine-2-thione-based histone deacetylase inhibitors., J Med Chem
    Yao Y et al., 2015, Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities., J Med Chem
    Johnson et al., 2015, HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma., Oncotarget
    Kerl et al., 2013, The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells., BMC Cancer
    Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.
    Alexandrova et al., 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment., Nature
    New et al., 2016, TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism., Cancer Res.
    Xu et al., 2005, The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines., Int. J. Mol. Med.
    Vinik et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol
    Geeleher P et al., 2015, Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics., J Natl Cancer Inst
    Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Garcia et al., 2016, Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species., Clin. Cancer Res.
    Kulp et al., 2006, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer., Clin. Cancer Res.
  • VORINOSTAT   CHD4

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26296641


    Sources:
    PharmGKB

  • VORINOSTAT   HDAC6

    Interaction Score: 0.69

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Merck
    Novel drug target Established target
    Mechanism of Interaction Histone deacetylase 6 inhibitor

    PMIDs:
    23622981 19966789 24766560 26211462 21696956 21080647 21548582 20491440 24304348 26331334 19084294 23672185 22260166 19344175 17694093


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions TEND

  • VORINOSTAT   HDAC2

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    Mechanism of Interaction Histone deacetylase 2 inhibitor
    Direct Interaction yes

    PMIDs:
    23622981 19966789 26211462 21548582 20491440 23672185 19084294 22260166 19344175 24074025 17447750 24694055 17694093


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions TEND

  • VORINOSTAT   HDAC3

    Interaction Score: 0.6

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Histone deacetylase 3 inhibitor
    Notes

    PMIDs:
    17447750 23622981 19966789 26211462 24694055 23672185 21548582 20491440 19084294 22260166 19344175 17694093


    Sources:
    TALC DTC TdgClinicalTrial ChemblInteractions TEND

  • VORINOSTAT   HDAC1

    Interaction Score: 0.57

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Histone deacetylase 1 inhibitor
    Direct Interaction yes
    Trial Name Merck

    PMIDs:
    17694093 11752352 23622981 19966789 26211462 21548582 20491440 24694055 19084294 23672185 22260166 19344175 18381238


    Sources:
    TALC DTC MyCancerGenome TdgClinicalTrial ChemblInteractions TEND TTD

  • VORINOSTAT   MYD88

    Interaction Score: 0.54

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type diffuse large B-cell lymphoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    27733371


    Sources:
    JAX-CKB

  • VORINOSTAT   HDAC9

    Interaction Score: 0.5

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC MyCancerGenome ClearityFoundationClinicalTrial

  • VORINOSTAT   HDAC11

    Interaction Score: 0.49

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC ClearityFoundationClinicalTrial

  • VORINOSTAT   BAP1

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22038994


    Sources:
    CIViC

  • VORINOSTAT   HDAC10

    Interaction Score: 0.45

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    21548582 20491440 19084294 22260166 19344175 23622981 19966789 26211462


    Sources:
    TALC DTC ClearityFoundationClinicalTrial

  • VORINOSTAT   HDAC8

    Interaction Score: 0.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    23622981 19966789 26211462 25974739 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC TEND

  • VORINOSTAT   HDAC7

    Interaction Score: 0.42

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC MyCancerGenome

  • VORINOSTAT   HDAC4

    Interaction Score: 0.41

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    18381238 23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC MyCancerGenome

  • VORINOSTAT   SMARCB1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fenretinide + Vorinostat
    Indication/Tumor Type rhabdoid cancer
    Response Type sensitive

    PMIDs:
    23764045


    Sources:
    JAX-CKB

  • VORINOSTAT   HDAC5

    Interaction Score: 0.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    23622981 19966789 26211462 21548582 20491440 19084294 22260166 19344175


    Sources:
    TALC DTC

  • VORINOSTAT   EZH2

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type diffuse large B-cell lymphoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    25605023


    Sources:
    JAX-CKB

  • VORINOSTAT   FBXW7

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type head and neck squamous cell carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    23274910


    Sources:
    JAX-CKB

  • VORINOSTAT   NPM1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy Ixazomib + Vorinostat
    Indication/Tumor Type acute myeloid leukemia

    PMIDs:
    26634271


    Sources:
    JAX-CKB

  • VORINOSTAT   RB1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type retinoblastoma
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    18483379 23498719


    Sources:
    JAX-CKB

  • VORINOSTAT   CFTR

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19966789


    Sources:
    DTC

  • VORINOSTAT   NR0B1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VORINOSTAT   TUBA3C

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB4A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   BIRC5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16951239


    Sources:
    NCI

  • VORINOSTAT   MYC

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15583844


    Sources:
    NCI

  • VORINOSTAT   TUBB6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB2B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA4A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB8

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA1C

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA3E

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA1B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA3D

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB2A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBA1A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB4B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   TUBB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20491440


    Sources:
    DTC

  • VORINOSTAT   ACE

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24074025


    Sources:
    DTC

  • VORINOSTAT   PTEN

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy GDC-0941 + vorinostat
    Indication/Tumor Type prostate cancer
    Response Type sensitive

    PMIDs:
    9661880 22693356


    Sources:
    JAX-CKB

  • VORINOSTAT   BRAF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell line xenograft
    Response Type sensitive

    PMIDs:
    27924459


    Sources:
    JAX-CKB

  • VORINOSTAT   PAX8

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VORINOSTAT   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pazopanib + Vorinostat
    Indication/Tumor Type Advanced Solid Tumor
    Response Type decreased response

    PMIDs:
    25669829 26009011


    Sources:
    JAX-CKB CIViC

  • VORINOSTAT   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • VORINOSTAT   NFE2L2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: VORINOSTAT

    • Version: 01-August-2011

    Alternate Names:
    VORINOSTAT Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 2006

    Publications:

  • MyCancerGenome: VORINOSTAT

    • Version: 20-Jun-2017

    Alternate Names:
    ZOLINZA Trade Name

    Drug Info:
    Drug Class Small molecule inhibitor
    FDA Approval Cutaneous T-cell lymphoma

    Publications:

  • TdgClinicalTrial: VORINOSTAT

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: VORINOSTAT

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL98 ChEMBL Drug ID

    Drug Info:

    Publications:
    Souto JA et al., 2010, Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues., J Med Chem
    Grolla AA et al., 2009, Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases., J Med Chem
    Hutt DM et al., 2010, Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis., Nat Chem Biol

  • NCI: SAHA

    • Version: 14-September-2017

    Alternate Names:
    C1796 NCI drug code

    Drug Info:

    Publications:
    Xu et al., 2005, The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines., Int. J. Mol. Med.
    Kulp et al., 2006, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer., Clin. Cancer Res.

  • JAX-CKB: Vorinostat

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    New et al., 2016, TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism., Cancer Res.
    Garcia et al., 2016, Selective Toxicity of Investigational Ixazomib for Human Leukemia Cells Expressing Mutant Cytoplasmic NPM1: Role of Reactive Oxygen Species., Clin. Cancer Res.
    Kerl et al., 2013, The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells., BMC Cancer

  • JAX-CKB: vorinostat

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Vlietstra et al., 1998, Frequent inactivation of PTEN in prostate cancer cell lines and xenografts., Cancer Res.

  • PharmGKB: vorinostat

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Geeleher P et al., 2015, Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics., J Natl Cancer Inst

  • CIViC: VORINOSTAT

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
    Fu et al., 2015, Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation., Ann. Oncol.

  • TALC: VORINOSTAT

    • Version: 12-May-2016

    Alternate Names:
    VORINOSTAT Primary Drug Name
    VORINOSTAT Drug Generic Name
    ZOLINZA Drug Trade Name

    Drug Info:

    Publications:

  • TTD: Vorinostat

    • Version: 2020.06.01

    Alternate Names:
    D0E7PQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL98

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: VORINOSTAT

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL98

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: VORINOSTAT

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21